Samsung Bio's new $668M client; Sanofi expands a factory in France
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Samsung Biologics has secured a number of ...
View ArticleTrump and RFK Jr. want to ban pharma ads. History isn't on their side
As the healthcare priorities of President-elect Donald Trump and his HHS pick Robert F. Kennedy Jr. take shape, one idea gaining steam is a ban on direct-to-consumer pharmaceutical advertising. Both...
View ArticleAt Jefferies, all that manufacturers want to talk about is GLP-1s
LONDON — Thousands of delegates flooded into the narrow corridors of the Waldorf Hilton this week to attend the Jefferies London Healthcare Conference. It was so busy that at one point, security had to...
View ArticleJazz wins approval for bispecific in biliary tract cancer
Jazz Pharmaceuticals earned an FDA approval on Wednesday for zanidatamab, the HER2-targeted bispecific antibody it picked up from Zymeworks for $50 million upfront. The drug, to be marketed as Ziihera,...
View ArticleAstraZeneca culls Phase 2 opioid use disorder drug
AstraZeneca ended a Phase 2 trial of an experimental opioid use disorder treatment, the UK pharma confirmed to Endpoints News. The termination was due to “discontinuation of the AZD4041 clinical...
View ArticleFDA adcomm raises risk questions on AstraZeneca’s Andexxa
Members of an FDA advisory committee were not asked to vote Thursday on AstraZeneca’s anticoagulant reversal drug Andexxa, but they did raise several safety and efficacy concerns. Last year,...
View ArticleWith yearslong reorganization behind it, Novartis increases its sales guidance
Novartis’ reorganization is paying off, CEO Vas Narasimhan told investors at an event Thursday in London. The company raised its sales guidance through 2028 and now expects to grow sales at a 6% annual...
View ArticlePatient dies in Neurogene's Rett syndrome study
A female Rett syndrome patient died Wednesday after receiving Neurogene's gene therapy in a clinical trial, the company disclosed in a new regulatory filing, after saying earlier this week that she ...
View ArticleEnveda raises $130M for drugs in I&I, obesity and other areas
Biotech startup Enveda has raised a $130 million Series C, the Colorado company said Thursday morning. Founded and led by early Recursion employee Viswa Colluru, the startup will use the funds ...
View ArticleLilly's board undergoes more changes; Merck strategy chief joins Roger...
→ Eli Lilly has appointed Procter & Gamble CEO Jon Moeller to the board of directors, while Goldman Sachs operating partner Karen Walker will resign from the board on Dec. 31 ...
View ArticleNabla Bio moves closer to AI-created antibodies
Protein-making AI models have fueled the launch of a $1 billion startup and a Nobel Prize win in 2024, but are they ready to actually make drugs? Leaders of some of the largest startups working ...
View ArticleLexicon ends commercial work to focus on R&D
Lexicon Pharmaceuticals is reverting to a clinical development company after facing repeated setbacks at the FDA for its type 1 diabetes and chronic kidney disease drug. The Texas biotech is slashing...
View ArticleHalozyme withdraws €2B Evotec acquisition proposal
Halozyme Therapeutics said Friday that it has pulled its proposal to buy Evotec, a struggling German biotech that Halozyme said was "unwilling to engage" in deal talks. Last week, San Diego ...
View ArticleFrom vaccines to psychedelics, five drugmakers on what could change under a...
President-elect Donald Trump and Robert Kennedy, Jr. — his pick to head up the Department of Health and Human Services — were hot topics at the Jefferies London Healthcare Conference this week as...
View ArticleSenate committee advances pharma patent challenge bill
The Senate Judiciary Committee narrowly advanced a bill Thursday that would change the way the Patent Trial and Appeal Board operates, limiting the ability of parties to challenge patents in court and...
View ArticleDrug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders
Eli Lilly and Novo Nordisk have filed dozens of lawsuits against compounding pharmacies marketing their own versions of popular weight loss and diabetes drugs. A new legal strategy could put Lilly one...
View ArticleSanofi introduces new 340B payment model — report
Sanofi is proposing a new model for distributing drug discounts under the federal 340B program, according to the Wall Street Journal, in an effort that is almost certain to create pushback ...
View ArticleFDA approves BridgeBio's heart disease drug, setting up competition with...
The FDA approved BridgeBio’s acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label will give it a near-immediate boost against...
View ArticleTrump picks Johns Hopkins researcher Marty Makary to lead the FDA
President-elect Donald Trump selected Marty Makary to lead the FDA, choosing a Johns Hopkins University surgeon who has called the US government the “greatest perpetrator of misinformation during the...
View ArticleTrump picks former congressman and vaccine injury advocate to lead CDC
Physician, veteran and former Florida Congressman Dave Weldon is President-elect Donald Trump’s pick to lead the CDC, giving Robert F. Kennedy Jr. a key ally on his planned review of the safety of...
View Article